PE20060273A1 - Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3 - Google Patents

Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3

Info

Publication number
PE20060273A1
PE20060273A1 PE2005000566A PE2005000566A PE20060273A1 PE 20060273 A1 PE20060273 A1 PE 20060273A1 PE 2005000566 A PE2005000566 A PE 2005000566A PE 2005000566 A PE2005000566 A PE 2005000566A PE 20060273 A1 PE20060273 A1 PE 20060273A1
Authority
PE
Peru
Prior art keywords
sulfonamide
alkyl
modulators
receptor
tetrahydroisoquinolin
Prior art date
Application number
PE2005000566A
Other languages
English (en)
Inventor
Martin Juan Antonio Diaz
Bargueno Maria Dolores Jimenez
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34944870&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060273(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20060273A1 publication Critical patent/PE20060273A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE n ES 1-6; -(C)n- ES ALQUILIDENO C1-C6 OPCIONALMENTE SUSTITUIDO CON 1-4 SUSTITUYENTES SELECCIONADOS ENTRE HALOGENO, HIDROXI, NITRO, CIANO, ENTRE OTROS; R1 ES H, ALQUILO C1-C6; R2 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6 OPCIONALMENTE SUSTITUIDOS DE 1-4 SUSTITUYENTES SELECCIONADOS ENTRE HIDROXI, NITRO, AMINO, ENTRE OTROS; B ES NR3R4; R3 Y R4 SON CADA UNO ALQUILO C1-C6, H O PUEDEN FORMAR JUNTOS ALQUILIDENO C1-C3; AMINOCICLO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[3-(DIETILAMINO)PROPIL]-1,2,3,4-TETRAHIDRO-ISOQUINOLIN-7-SULFONAMIDA; N-[3-(DIETILAMINO)PROPIL]-N-METIL-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA; (+/-)-2-(CICLOPROPILMETIL)-N-[2-(1-PIRROLIDIN-2-IL)ETIL]-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR H3 DE LA HISTAMINA UTILES EN EL TRATAMIENTO DE OBESIDAD, DIABETES Y ENFERMEDADES DEL SNC TALES COMO LA VIGILIA Y EL SUENO
PE2005000566A 2004-05-25 2005-05-23 Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3 PE20060273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0405607A FR2870846B1 (fr) 2004-05-25 2004-05-25 Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique

Publications (1)

Publication Number Publication Date
PE20060273A1 true PE20060273A1 (es) 2006-04-22

Family

ID=34944870

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000566A PE20060273A1 (es) 2004-05-25 2005-05-23 Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3

Country Status (41)

Country Link
US (3) US7833999B2 (es)
EP (1) EP1753725B1 (es)
JP (1) JP4861979B2 (es)
KR (1) KR101176675B1 (es)
CN (1) CN1956962B (es)
AR (1) AR050250A1 (es)
AU (1) AU2005250197B2 (es)
BR (1) BRPI0511581A (es)
CA (1) CA2565293C (es)
CR (1) CR8735A (es)
CY (1) CY1114240T1 (es)
DK (1) DK1753725T3 (es)
DO (1) DOP2005000103A (es)
EA (1) EA010234B1 (es)
EC (1) ECSP067020A (es)
ES (1) ES2407140T3 (es)
FR (1) FR2870846B1 (es)
GT (1) GT200500126A (es)
HK (1) HK1106229A1 (es)
HN (1) HN2005000239A (es)
HR (1) HRP20130431T1 (es)
IL (1) IL179021A (es)
JO (1) JO2877B1 (es)
MA (1) MA28720B1 (es)
MX (1) MXPA06013629A (es)
MY (1) MY148980A (es)
NI (1) NI200600279A (es)
NO (1) NO338104B1 (es)
NZ (1) NZ551509A (es)
PA (1) PA8634501A1 (es)
PE (1) PE20060273A1 (es)
PL (1) PL1753725T3 (es)
PT (1) PT1753725E (es)
SI (1) SI1753725T1 (es)
SV (1) SV2006002126A (es)
TN (1) TNSN06356A1 (es)
TW (1) TWI360540B (es)
UA (1) UA84771C2 (es)
UY (1) UY28917A1 (es)
WO (1) WO2005118547A1 (es)
ZA (1) ZA200609820B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP1790646A1 (fr) * 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
WO2009063953A1 (ja) 2007-11-13 2009-05-22 Taisho Pharmaceutical Co., Ltd. フェニルピラゾール誘導体
TW201039822A (en) 2009-02-06 2010-11-16 Taisho Pharmaceutical Co Ltd Dihydroquinolinone derivatives
EP2445899B1 (en) 2009-06-26 2016-05-11 Sanofi Novel fumarate salts of a histamine h3 receptor antagonist
AR080374A1 (es) * 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida
WO2013085018A1 (ja) 2011-12-08 2013-06-13 大正製薬株式会社 フェニルピロール誘導体
US20150045553A1 (en) 2011-12-27 2015-02-12 Taisho Pharmaceutical Co., Ltd Phenyltriazole derivative
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
WO2015032966A1 (en) * 2013-09-09 2015-03-12 Sanofi An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
CN110642854A (zh) * 2019-11-20 2020-01-03 成都克莱蒙医药科技有限公司 一种稠环化合物的多晶型、其组合物、制备方法及其应用
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0702671A4 (en) * 1993-06-09 1996-06-19 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS
GB9508622D0 (en) * 1995-04-28 1995-06-14 Pfizer Ltd Therapeutic agants
NZ331272A (en) * 1996-02-09 2000-01-28 Black James Foundation Histamine H3 receptor ligands
IL138899A0 (en) 1998-04-10 2001-11-25 Japan Tobacco Inc Amidene derivatives and pharmaceutical compositions containing the same
US6545055B1 (en) 1999-05-24 2003-04-08 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP4031363B2 (ja) 2001-01-02 2008-01-09 エフ．ホフマン−ラ ロシュ アーゲー α−１Ａ／Ｂアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体
AU2002254114A1 (en) * 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
JP2003192660A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
US20050154230A1 (en) * 2001-12-26 2005-07-14 Bayer Healthcare Ag Urea derivatives
KR100984655B1 (ko) 2002-03-08 2010-10-01 사카타 인쿠스 가부시키가이샤 처리안료, 그 용도 및 안료처리용 화합물
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
BR0313923A (pt) * 2002-08-29 2005-07-12 Boehringer Ingelheim Pharma Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP1630158A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
ES2257168B1 (es) 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. Ligandos del receptor 5-ht7.
US20080261999A1 (en) 2005-03-04 2008-10-23 Fionna Mitchell Martin Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
EP1790646A1 (fr) * 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.

Also Published As

Publication number Publication date
CN1956962B (zh) 2014-08-20
ECSP067020A (es) 2006-12-29
WO2005118547A1 (fr) 2005-12-15
FR2870846B1 (fr) 2006-08-04
NI200600279A (es) 2008-01-22
US20120323003A1 (en) 2012-12-20
TW200609220A (en) 2006-03-16
ES2407140T3 (es) 2013-06-11
MA28720B1 (fr) 2007-07-02
DOP2005000103A (es) 2006-02-15
US20110028475A1 (en) 2011-02-03
FR2870846A1 (fr) 2005-12-02
JO2877B1 (en) 2015-03-15
CA2565293A1 (fr) 2005-12-15
CN1956962A (zh) 2007-05-02
NO338104B1 (no) 2016-08-01
NZ551509A (en) 2009-12-24
AR050250A1 (es) 2006-10-11
US7833999B2 (en) 2010-11-16
CY1114240T1 (el) 2016-08-31
US8273733B2 (en) 2012-09-25
KR20070021223A (ko) 2007-02-22
HRP20130431T1 (en) 2013-06-30
GT200500126A (es) 2006-02-17
UY28917A1 (es) 2005-12-30
IL179021A (en) 2012-04-30
MXPA06013629A (es) 2007-03-23
EA200602176A1 (ru) 2007-04-27
CR8735A (es) 2007-08-28
JP2008500313A (ja) 2008-01-10
ZA200609820B (en) 2008-06-25
PA8634501A1 (es) 2006-05-16
CA2565293C (fr) 2012-10-30
DK1753725T3 (da) 2013-05-27
MY148980A (en) 2013-06-28
AU2005250197A1 (en) 2005-12-15
BRPI0511581A (pt) 2008-01-02
UA84771C2 (uk) 2008-11-25
EA010234B1 (ru) 2008-06-30
US20070105834A1 (en) 2007-05-10
EP1753725B1 (fr) 2013-02-27
NO20065918L (no) 2006-12-19
AU2005250197B2 (en) 2010-09-23
SI1753725T1 (sl) 2013-06-28
JP4861979B2 (ja) 2012-01-25
PL1753725T3 (pl) 2013-07-31
EP1753725A1 (fr) 2007-02-21
IL179021A0 (en) 2007-03-08
TNSN06356A1 (en) 2008-02-22
KR101176675B1 (ko) 2012-08-23
HN2005000239A (es) 2009-04-27
PT1753725E (pt) 2013-05-21
SV2006002126A (es) 2006-01-13
HK1106229A1 (en) 2008-03-07
TWI360540B (en) 2012-03-21
US8524700B2 (en) 2013-09-03

Similar Documents

Publication Publication Date Title
PE20060273A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3
PE20040801A1 (es) Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20090641A1 (es) Amidas heterociclicas
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
AR049696A1 (es) Derivados de indol
AR057104A1 (es) Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica
PE20060623A1 (es) Compuestos de sulfonamida como potenciadores del receptor de glutamato
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
AR035722A1 (es) Derivados de indol, procesos para su preparacion, composiciones farmaceuticas que los comprenden y el uso de dichos compuestos para la produccion de medicamentos
JP2008506695A5 (es)
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
DE602005014786D1 (de) Oxazolderivate als histamin-h3-rezeptor-wirkstoffe, deren herstellung und therapeutische verwendung
PE20081314A1 (es) COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20041078A1 (es) Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
PE20060572A1 (es) Compuestos de benzoimidazolona como inhibidores de hsp90
PE20040772A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed